BCH
Based on 11 publication(s) in Google Scholar
BCH (2-Amino-2-norbornanecarboxylic acid) is a selective and competitive inhibitor of large neutral amino acid transporter 1 (LAT1) significantly inhibit cellular uptake of amino acids and mTOR phosphorylation, which induces the suppression of cancer growth and apoptosis.
Para uso exclusivo en investigación. No vendemos a pacientes.
- Pureza: 99.13%
- No. CAS: 20448-79-7
- Fòrmula: C8H13NO2
- Peso molecular:155.20
-
Almacenamiento:
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
To place orders, for customer services and technical support, please contact: MedChemExpress USA
Tel: 609-228-6898 E-mail: [email protected] [email protected]
-
Actividad biológica
-
Chemical Information
-
Solvente y solubilidad
- Pureza y Documentación
- Referencias
-
Help & FAQs
-
Apoptosis Compound Library
HY-L003
-
Anti-Cancer Compound Library
HY-L025
-
Targeted Diversity Library
HY-L099
-
Human Metabolite Library
HY-L123
-
Highly Selective Activators Library
HY-L159
-
Cell Death Library
HY-L162
-
Bioactive Compound Library Max
HY-L181
-
MCE Bioactive Compound Library
HY-L001V
-
Bioactive Compound Library
HY-L001
-
Non-Alcoholic Fatty Liver Disease (NAFLD) Compound Library
HY-L199
-
High-Throughput Bioactive Compound Library
HY-L205
-
Mass Spectrometry Human Metabolite Library
HY-L215
-
3D Diverse Fragment Library
HY-L903
Publications Citing Use of MedChemExpress (MCE) BCH
More- Cancer Commun (Lond). 2024 May 12. [Abstract]
- Nat Immunol. 2023 Dec;24(12):2042-2052. [Abstract]
- Nat Immunol. 2023 Oct;24(10):1685-1697. [Abstract]
- Cell Host Microbe. 2025 Sep 30:S1931-3128(25)00375-0. [Abstract]
- Acta Pharm Sin B. 2024 Aug;14(8):3493-3512. [Abstract]
- Adv Sci (Weinh). 2024 Jul 1:e2402086. [Abstract]
- Mol Ther. 2024 May 10:S1525-0016(24)00319-8. [Abstract]
- Mol Med. 2025 Oct 21;31(1):315. [Abstract]
- Front Immunol. 2022 May 19:13:880262. [Abstract]
- J Agric Food Chem. 2025 Dec 17;73(50):31783-31793. [Abstract]
- bioRxiv. 2025 Jan 29:2025.01.27.635146. [Abstract]
Customer Validation & Images
-
Flow Cytometry
-
WB
-
Flow Cytometry
-
Cell Imaging/Staining
-
WB
Actividad biológica
LAT1[1]
|
Cell Line
|
Type | Value | Description | References |
|---|---|---|---|---|
| LNCaP | IC50 |
4060 μM
Compound: BCH
|
Inhibition of LAT in human LNCAP cells assessed as inhibition of [3H]-L-leucine transport by liquid scintillation counting analysis
Inhibition of LAT in human LNCAP cells assessed as inhibition of [3H]-L-leucine transport by liquid scintillation counting analysis
|
[PMID: 25984885] |
| MCF7 | IC50 |
112 μM
Compound: BCH
|
Competitive inhibition of [14C]-L-leucine uptake at LAT1 in human MCF7 cells preincubated for 5 mins followed by addition of substrate measured during 5 mins by liquid scintillation counting
Competitive inhibition of [14C]-L-leucine uptake at LAT1 in human MCF7 cells preincubated for 5 mins followed by addition of substrate measured during 5 mins by liquid scintillation counting
|
[PMID: 27253989] |
| MCF7 | IC50 |
362 μM
Compound: BCH
|
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye-based fluorimetric analysis
Antiproliferative activity against human MCF7 cells assessed as reduction in cell viability measured after 72 hrs by resazurin dye-based fluorimetric analysis
|
[PMID: 27253989] |
BCH (1-100 mM; 3 days; KYSE30 and KYSE150 esophageal cancer cells) treatment suppresses cell proliferation in a dose-dependent manner[1].
BCH (30 mM; 24 and 48 hours; KYSE30 and KYSE150 cells) treatment significantly increases cell population in the G0/G1 phase in both KYSE30 and KYSE150 cells, indicating that BCH induces cell cycle arrest at G1 phase[1].
BCH (30 mM; 0-24 hours; KYSE30 and KYSE150 cells) treatment decreases phosphorylation of 4E-BP1 and p70S6K at 30 minutes and the decrease is continued for 24 hours. The amount of mTOR, 4E-BP1, and p70S6K proteins is slightly decreased[1].
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Cell Line:KYSE30 and KYSE150 esophageal cancer cells
-
Concentration:1 mM, 3 mM, 5 mM, 10 mM, 20 mM, 30 mM, 40 mM, 50 mM, or 100 mM
-
Incubation Time:3 days
-
Result:Cell proliferation was suppressed in a dose-dependent manner.
-
Cell Line:KYSE30 and KYSE150 cells
-
Concentration:30 mM
-
Incubation Time:24 and 48 hours
-
Result:Cell cycle arrest.
-
Cell Line:KYSE30 and KYSE150 cells
-
Concentration:30 mM
-
Incubation Time:0 hour, 0.5 hour, 1 hour, 3 hours, 6 hours, 24 hours
-
Result:Phosphorylation of 4E-BP1 and p70S6K was decreased. The amount of mTOR, 4E-BP1, and p70S6K proteins was slightly decreased.
MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.
-
Animal Model:Male BALB/c nude mice (5-week-old) with KYSE150 cells[1]
-
Dosage:200 mg/kg
-
Administration:Intravenous injection; daily; for 14 days
-
Result:Significantly delayed tumor growth and decreased glucose metabolism.
| NCT Number | Sponsor | Condition | Start Date |
Phase
|
|---|---|---|---|---|
| NCT01329991 | Plexxikon| | 2011-05 | PHASE1 |
Chemical Information
-
No. CAS 20448-79-7
-
Appearance Solid
-
Peso molecular 155.20
-
Fòrmula C8H13NO2
-
Color White to off-white
-
SMILES
O=C(C1(N)C(C2)CCC2C1)O
-
Synonyms
2-Amino-2-norbornanecarboxylic acid; LAT1-IN-1
-
Envío
Room temperature in continental US; may vary elsewhere.
-
Almacenamiento
4°C, sealed storage, away from moisture
* In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)
Publications (11)
-
Journal Impact Factor
-
Most Recent
-
Cancer Commun (Lond)
Metabolic landscape of head and neck squamous cell carcinoma informs a novel kynurenine/Siglec-15 axis in immune escape. [Abstract]2024 May 12. PMID: 38734931
BCH purchased from MedChemExpress. Usage Cited in: Cancer Commun (Lond). 2024 May 12. [Abstract]
Kyn (100 µmol/L) and the system L inhibitor, BCH (5 mmol/L) were used as the indicated treatments to analyze the functions of Kyn on the dysfunction of primary CD8+ T cells and Jurkat cells (48 h).
-
Nat Immunol
Tumor cell-released kynurenine biases MEP differentiation into megakaryocytes in individuals with cancer by activating AhR-RUNX1. [Abstract]2023 Dec;24(12):2042-2052. PMID: 37919525
BCH purchased from MedChemExpress. Usage Cited in: Nat Immunol. 2023 Dec;24(12):2042-2052. [Abstract]
Murine MEPs were treated with Kyn or Kyn combine with BCH (100 μM) for 48 h, MEPs were stained for AhR.
-
Nat Immunol
2023 Oct;24(10):1685-1697. PMID: 37697097 -
Cell Host Microbe
Immunometabolic reprogramming of macrophages by gut microbiota-derived cadaverine controls colon inflammation. [Abstract]2025 Sep 30:S1931-3128(25)00375-0. PMID: 41033313 -
Acta Pharm Sin B
Phenylalanine deprivation inhibits multiple myeloma progression by perturbing endoplasmic reticulum homeostasis. [Abstract]2024 Aug;14(8):3493-3512. PMID: 39220878 -
Adv Sci (Weinh)
Branched-Chain Amino Acids Deficiency Promotes Diabetic Neuropathic Pain Through Upregulating LAT1 and Inhibiting Kv1.2 Channel. [Abstract]2024 Jul 1:e2402086. PMID: 38946582
BCH purchased from MedChemExpress. Usage Cited in: Adv Sci (Weinh). 2024 Jul 1:e2402086. [Abstract]
Western blot analysis of ATF4, LAT1, and 4F2hc expression in Neuro‐2a cells treated with BCAA deficiency or BCH.
-
Mol Ther
BCKDK modification enhances the anticancer efficacy of CAR-T cells by reprogramming branched chain amino acid metabolism. [Abstract]2024 May 10:S1525-0016(24)00319-8. PMID: 38734897
BCH purchased from MedChemExpress. Usage Cited in: Mol Ther. 2024 May 10:S1525-0016(24)00319-8. [Abstract]
BCH decreased intracellular IFN-γ and TNF-α production.
-
Mol Med
2025 Oct 21;31(1):315. PMID: 41120907 -
Front Immunol
Targeting Glutamine Metabolism Ameliorates Autoimmune Hepatitis via Inhibiting T Cell Activation and Differentiation. [Abstract]2022 May 19:13:880262. PMID: 35663990
BCH purchased from MedChemExpress. Usage Cited in: Front Immunol. 2022 May 19:13:880262. [Abstract]
LAT1-IN1 (30 nM) inhibits the expression levels of phosphorylated mTOR and P70S6K in T cells.
-
J Agric Food Chem
2025 Dec 17;73(50):31783-31793. PMID: 41329159 -
bioRxiv
Metabolic Adaptations Rewire CD4 T Cells in a Subset-Specific Manner in Human Critical Illness with and without Sepsis. [Abstract]2025 Jan 29:2025.01.27.635146. PMID: 39975258
Solvente y solubilidad
H2O : 20 mg/mL (128.87 mM; ultrasonic and warming and heat to 60°C)
DMSO : < 1 mg/mL (insoluble or slightly soluble)
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
Concentration (start) × Volume (start) = Concentration (final) × Volume (final)
For the following dissolution methods, please prepare the working solution directly:
It is recommended to prepare fresh solutions and use them promptly within a short period of time.
The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.
Add each solvent one by one: PBS
Solubility: 12.5 mg/mL (80.54 mM); Clear solution; Need ultrasonic and warming and heat to 60°C
Pureza y Documentación
-
Ficha de datos (285 KB)
-
SDS (393 KB)
- English - EN (393 KB)
- Français - FR (393 KB)
- Deutsch - DE (393 KB)
- Norwegian - NO (393 KB)
- Español - ES (393 KB)
- Swedish - SV (393 KB)
- Italian - IT (393 KB)
- Korean - KR (393 KB)
- Portuguese - PT (393 KB)
-
Instrucciones de manejo (2659 KB)
Referencias
[1]. Ohshima Y, et al. Efficacy of system l amino acid transporter 1 inhibition as a therapeutic target in esophageal squamous cell carcinoma. Cancer Sci. 2016 Oct;107(10):1499-1505. [Content Brief]
[2]. Singh N, et al. Discovery of Potent Inhibitors for the Large Neutral Amino Acid Transporter 1 (LAT1) by Structure-Based Methods. Int J Mol Sci. 2018 Dec 21;20(1). [Content Brief]
[3]. Wang Q, et al. L-type amino acid transport and cancer: targeting the mTORC1 pathway to inhibit neoplasia. Am J Cancer Res. 2015 Mar 15;5(4):1281-94. eCollection 2015. [Content Brief]
Complete Stock Solution Preparation Table
Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.
| Optional Solvent | Concentration Solvent Mass | 1 mg | 5 mg | 10 mg | 25 mg |
|---|---|---|---|---|---|
| H2O | 1 mM | 6.4433 mL | 32.2165 mL | 64.4330 mL | 161.0825 mL |
| 5 mM | 1.2887 mL | 6.4433 mL | 12.8866 mL | 32.2165 mL | |
| 10 mM | 0.6443 mL | 3.2216 mL | 6.4433 mL | 16.1082 mL | |
| 15 mM | 0.4296 mL | 2.1478 mL | 4.2955 mL | 10.7388 mL | |
| 20 mM | 0.3222 mL | 1.6108 mL | 3.2216 mL | 8.0541 mL | |
| 25 mM | 0.2577 mL | 1.2887 mL | 2.5773 mL | 6.4433 mL | |
| 30 mM | 0.2148 mL | 1.0739 mL | 2.1478 mL | 5.3694 mL | |
| 40 mM | 0.1611 mL | 0.8054 mL | 1.6108 mL | 4.0271 mL | |
| 50 mM | 0.1289 mL | 0.6443 mL | 1.2887 mL | 3.2216 mL | |
| 60 mM | 0.1074 mL | 0.5369 mL | 1.0739 mL | 2.6847 mL | |
| 80 mM | 0.0805 mL | 0.4027 mL | 0.8054 mL | 2.0135 mL | |
| 100 mM | 0.0644 mL | 0.3222 mL | 0.6443 mL | 1.6108 mL |
* Note: If you choose water as the stock solution, please dilute it to the working solution, then filter and sterilize it with a 0.22 μm filter before use.
BCH Related Classifications
HY-108540 Related Classifications
Powered by Bioz